FOR IMMEDIATE RELEASE
January 5, 2023 Ann Arbor, MI
Genomenon®, Inc., an AI-driven genomics company, announced today that it will participate in BIO Partnering at JPM, January 9-12, 2023 in San Francisco.
Details of the event are as follows:
Event: BIO Partnering @ JPM
Date: January 9-12, 2023
Registration: https://www.bio.org/events/bio-partnering-jpm/registration
Members of the Genomenon leadership team will be available to participate in one-on-one meetings with registered pharmaceutical companies and investors to raise awareness of the cost of incomplete genomic information at every stage in the drug discovery process for rare disease therapeutics. To schedule a meeting with the Genomenon team, please reach out through the BIO Partnering system.
Genomenon is a real-world evidence and genomic intelligence company that partners with pharmaceutical organizations to accelerate drug development in rare disease and precision oncology. By transforming biomedical literature into structured, evidence-based real-world evidence, Genomenon strengthens disease understanding, informs clinical trial design, and supports regulatory and label expansion strategies. Genomenon empowers pharma teams with high-confidence, literature-derived insights that drive smarter, data-driven decisions across the drug development lifecycle.
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations.
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
For more information, visit www.bio.org
